S55746 BCL201|cas:1448584-12-0|西域试剂

S55746 BCL201,99.66%

产品编号：Bellancom-117288| CAS NO：1448584-12-0| 分子式：C₄₃H₄₂N₄O₆| 分子量：710.82

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-117288	￥1250.00	杭州北京（现货）
Bellancom-117288	￥2200.00	杭州北京（现货）
Bellancom-117288	￥4500.00	杭州北京（现货）
Bellancom-117288	￥8100.00	杭州北京（现货）
Bellancom-117288	￥15000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

S55746 BCL201

产品介绍

S55746 (BCL201) 是一种有效、可口服、选择性的 BCL-2 抑制剂，其 K_i 值和 K_d 值分别为 1.3 nM 和 3.9 nM。S55746 (BCL201) 具有抗肿瘤活性且毒性低。

生物活性

S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a K_i of 1.3 nM and a K_d of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity.

体外研究

S55746 (0-1 μM) potently and selectively induces cell death.
S55746 selectively induces apoptosis through BCL-2 inhibition in a BAX/BAK-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	H146 and RS4;11 cell lines.
Concentration:	0, 0.1, 0.3 and 1 μM.
Incubation Time:	72 hours.
Result:	Potently induced RS4;11 cell killing after 72 h of treatment with an IC₅₀ of 71.6 nM.

体内研究
(In Vivo)

S55746 is a highly efficacious and well-tolerated (even at doses up to 300 mg/kg) orally active BCL-2 inhibitor .
S55746 (20-100 mg/kg, p.o.) inhibits xenograft growth in RS4;11 and Toledo models time- and dose-dependently.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SCID/beige mice implanted subcutaneously with 3×10⁶ Toledo or RS4;11.
Dosage:	20, 50, 100 mg/kg.
Administration:	Oral gavage daily for 7 consecutive days.
Result:	Induced significant anti-tumor activity time- and dose-dependently.

Animal Model:	SCID/beige female mice with RS4;11 tumor xenografts.
Dosage:	25 and 100 mg/kg.
Administration:	Single oral gavage treatment.
Result:	Did not induce platelet loss in vivo at 25 and 100 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SCID/beige mice implanted subcutaneously with 3×10⁶ Toledo or RS4;11.
Dosage:	20, 50, 100 mg/kg.
Administration:	Oral gavage daily for 7 consecutive days.
Result:	Induced significant anti-tumor activity time- and dose-dependently.

Animal Model:	SCID/beige female mice with RS4;11 tumor xenografts.
Dosage:	25 and 100 mg/kg.
Administration:	Single oral gavage treatment.
Result:	Did not induce platelet loss in vivo at 25 and 100 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SCID/beige mice implanted subcutaneously with 3×10⁶ Toledo or RS4;11.
Dosage:	20, 50, 100 mg/kg.
Administration:	Oral gavage daily for 7 consecutive days.
Result:	Induced significant anti-tumor activity time- and dose-dependently.

Animal Model:	SCID/beige female mice with RS4;11 tumor xenografts.
Dosage:	25 and 100 mg/kg.
Administration:	Single oral gavage treatment.
Result:	Did not induce platelet loss in vivo at 25 and 100 mg/kg.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (70.34 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.4068 mL	7.0341 mL	14.0683 mL
5 mM	0.2814 mL	1.4068 mL	2.8137 mL
10 mM	0.1407 mL	0.7034 mL	1.4068 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 5.75 mg/mL (8.09 mM); Suspended solution; Need ultrasonic

此方案可获得 5.75 mg/mL (8.09 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 57.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.52 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.52 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。